Mutant NPM1: Nuclear export and the mechanism of leukemogenesis
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26862
Abstract: NPM1 -mutated acute myeloid leukemia (AML) represents the most frequent genetic subtype of AML, accounting for about 30% to 35% of newly diagnosed cases in adults. 1 Because of its distinctive clinico-pathological and molecular features,… read more here.
Keywords: mutant npm1; npm1 mutated; npm1 nuclear; nuclear export ... See more keywords
Measurable residual disease, FLT3‐ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1‐mutated acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4218
Abstract: Nucleophosmin‐1 (NPM1) mutations in acute myeloid leukemia (AML) confer a survival advantage in the absence of FLT3‐internal tandem duplication (FLT3‐ITD). Here, we investigated the main predictors of outcome after allogeneic hematopoietic stem cell transplantation (allo‐HCT).… read more here.
Keywords: disease; npm1 mutated; status; acute myeloid ... See more keywords
Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia"
DOI: 10.1038/s41375-021-01222-4
Abstract: Mutations of Nucleophosmin (NPM1) are the most common genetic abnormalities in adult acute myeloid leukaemia (AML), accounting for about 30% of cases. NPM1-mutated AML has been recognized as distinct entity in the 2017 World Health… read more here.
Keywords: diagnostic therapeutic; mutated aml; therapeutic pitfalls; cases npm1 ... See more keywords
Biological and therapeutic implications of a unique subtype of NPM1 mutated AML
Sign Up to like & getrecommendations! Published in 2021 at "Nature Communications"
DOI: 10.1038/s41467-021-21233-0
Abstract: In acute myeloid leukemia (AML), molecular heterogeneity across patients constitutes a major challenge for prognosis and therapy. AML with NPM1 mutation is a distinct genetic entity in the revised World Health Organization classification. However, differing… read more here.
Keywords: biological therapeutic; therapeutic implications; mutated aml; drug ... See more keywords
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of haematology"
DOI: 10.1111/bjh.18887
Abstract: NPM1-mutated acute myeloid leukaemia (NPM1mut AML) represents a mostly favourable/intermediate risk disease that benefits from allogeneic haematopoietic stem cell transplantation (HSCT) in case of measurable residual disease (MRD) relapse or persistence after induction chemotherapy. Although… read more here.
Keywords: mutated acute; npm1 mutated; acute myeloid; molecular failure ... See more keywords
Frequency and Stimulation of NPM1-Specific Immune Responses By Anti-PD1 Antibodies in NPM1-Mutated AML
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-134876
Abstract: Nucelophosmin1 (NPM1) is one of the most commonly mutated genes in AML, represents a distinct entity according to the WHO and is commonly associated with a favorable prognosis. We described specific immune responses against immunogenic… read more here.
Keywords: reduction; npm1 specific; npm1mut patients; specific immune ... See more keywords
How I diagnose and treat NPM1-mutated AML.
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2020008211
Abstract: Mutations of the nucleophosmin (NPM1) gene, encoding for a nucleolar multifunctional protein, occur in about one-third of adult acute myeloid leukemia (AML). NPM1-mutated AML exhibits unique molecular, pathological and clinical features, that led to its… read more here.
Keywords: diagnosis; diagnose treat; mutated aml; npm1 mutated ... See more keywords
Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients
Sign Up to like & getrecommendations! Published in 2017 at "Haematologica"
DOI: 10.3324/haematol.2017.171645
Abstract: Long non-coding RNAs are defined as transcripts larger than 200 nucleotides but without protein-coding potential. There is growing evidence of the important role of long non-coding RNAs in cancer initiation, development and progression. In this… read more here.
Keywords: cytogenetically normal; long non; non coding; expression ... See more keywords
Targeted therapy in NPM1-mutated AML: Knowns and unknowns
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.972606
Abstract: Acute myeloid leukemia (AML) is a heterogeneous disease characterized by malignant proliferation of myeloid hematopoietic stem/progenitor cells. NPM1 represents the most frequently mutated gene in AML and approximately 30% of AML cases carry NPM1 mutations.… read more here.
Keywords: therapy npm1; targeted therapy; npm1 mutated; mutated aml ... See more keywords
Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1mut) for the Treatment of NPM1mut-Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15102731
Abstract: Simple Summary Nearly 30% of adult acute myeloid leukemias (AML) harbor mutations of the nucleophosmin (NPM1) gene. These forms have a favorable outcome but, despite notable treatment advances, about 50% of patients still die of… read more here.
Keywords: mutated npm1; npm1 mutated; acute myeloid; treatment ... See more keywords
Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms19113492
Abstract: Acute myeloid leukemia (AML) with NPM1 gene mutations is currently recognized as a distinct entity, due to its unique biological and clinical features. We summarize here the results of published studies investigating the clinical application… read more here.
Keywords: mrd; myeloid leukemia; monitoring; npm1 mutated ... See more keywords